{
    "id": "dbpedia_6046_2",
    "rank": 8,
    "data": {
        "url": "https://www.sinopharmtech.com.hk/",
        "read_more_link": "",
        "language": "en",
        "title": "Sinopharm Tech Holdings Limited",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://www.sinopharmtech.com.hk/images/logo.jpg",
            "https://www.sinopharmtech.com.hk/images/stockcode.jpg",
            "https://www.sinopharmtech.com.hk/images/chi.jpg",
            "https://www.sinopharmtech.com.hk/images/gb.jpg",
            "https://www.sinopharmtech.com.hk/images/sidebar/nav_top.jpg",
            "https://www.sinopharmtech.com.hk/images/sidebar/profile_off.png",
            "https://www.sinopharmtech.com.hk/images/sidebar/businesses_off.png",
            "https://www.sinopharmtech.com.hk/images/sidebar/fr_off.png",
            "https://www.sinopharmtech.com.hk/images/sidebar/ann_off.png",
            "https://www.sinopharmtech.com.hk/images/sidebar/governance_off.png",
            "https://www.sinopharmtech.com.hk/images/sidebar/cd_off.png",
            "https://www.sinopharmtech.com.hk/images/sidebar/corpinfo_off.png",
            "https://www.sinopharmtech.com.hk/images/sidebar/nav_bottom.png",
            "https://www.sinopharmtech.com.hk/images/back2top_arrow.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "Corporate Profile\n\nSinopharm Tech Holdings Limited (“Sinopharm Tech”) was founded in 1999. Sinopharm Tech was successfully listed on GEM of The Stock Exchange of Hong Kong Limited in November 2002. Stock code: 8156.\n\nThe Group continued to accelerate its deployment in the healthcare industry. Through establishing a subsidiary in the PRC, the Group has completed the relevant deployment in respect of the development of the distribution of Chinese patent medicines and health products, which provides new revenue streams and business development direction to the Group. The Group has continued to develop its supply chain business under the “Internet Plus” services, and achieved a stable development during the period under review. Meanwhile, the Group is also discussing the model of cooperation with various industry operators and product suppliers to provide them value-added services leveraging on the Group’s experience in the “Internet Plus” business. The above cooperation will bring new opportunities for the Group in the “Internet Plus” business and mark the acceleration of the Group’s application of the “Internet Plus” business in different business models."
    }
}